Furthermore, a randomized controlled trial on whether to adopt the protocol of trastuzumab-containing adjuvant therapy among patients whose cancer lose HER2 expression not only in the primary tumor but also in the synchronous metastatic nodal lesions after NAC should be carried out. Here, ERBB2 is linked to cancer.